Vinpocetine

Vinpocetine, chemically known as ethyl apovincaminate, is a semisynthetic derivative of the vinca alkaloid vincamine, which is obtained from the leaves of the lesser periwinkle (Vinca minor) or from the seeds of Voacanga africana ^[1][3]. It was discovered and developed in Hungary in the late 1960s, and the pharmaceutical company Gedeon Richter has marketed it under the brand name Cavinton ^[1][4]. Structurally it differs from vincamine by the removal of a hydroxyl group and an ester modification ^[3].

For over thirty years vinpocetine has been prescribed in a number of European and Asian countries to treat cerebrovascular conditions, including recovery after stroke and various forms of cognitive impairment and dementia ^[1][3]. In much of the world outside those markets it is instead encountered as a dietary supplement promoted to enhance memory, concentration and general cognition ^[1]. Interest has also grown in possible new uses, with laboratory research pointing to anti-inflammatory and cardiovascular effects that could broaden its potential applications ^[1][2].

The clinical evidence for vinpocetine is mixed and generally regarded as limited ^[3]. Studies have shown that intravenous vinpocetine can increase blood flow and oxygen delivery to compromised brain tissue in people who have had a stroke ^[4], and a large controlled trial in China reported that adding vinpocetine to standard care for acute cerebral infarction improved measures of cognition, neurological function and quality of life ^[5]. On the other hand, a systematic review of its use in dementia concluded that the available trials were old and too limited to support routine clinical use ^[3].

Regulatory treatment of vinpocetine differs sharply between regions ^[1]. In the European Union and several other countries it is a prescription medicine, whereas in the United States the Food and Drug Administration has determined that it does not qualify as a lawful dietary-supplement ingredient and has warned that it should not be sold in supplements; the agency has also cautioned that vinpocetine may harm a developing fetus and should be avoided by women who are pregnant or may become pregnant ^[1]. Analyses of supplement products have found that the actual vinpocetine content often fails to match the label. Reported side effects are usually mild and include facial flushing, nausea, dizziness, dry mouth, headache and temporary changes in blood pressure ^[1].

Vinpocetine can lower blood pressure, so be careful pairing it with antihypertensives or blood thinners (warfarin, aspirin, NSAIDs) because bleeding risk adds up. Avoid it in pregnancy; animal studies show birth defects, and the FDA warned in 2019 that it can't legally be sold as a dietary supplement in the US. It's a prescription drug in Germany, Hungary, and several Asian countries (sold as Cavinton). Anyone with a bleeding disorder, on antiplatelet or anticoagulant therapy, pregnant or breastfeeding, or allergic to vinca alkaloids should steer clear.

Vinpocetine is a semisynthetic derivative of vincamine, an alkaloid of the lesser periwinkle (Vinca minor). It was developed in Hungary, where the chemist Csaba Szantay and co-workers characterized the vincamine chemistry and the compound was synthesized in the late 1960s and patented in the early 1970s. The pharmaceutical company Gedeon Richter began manufacturing it in 1978 and marketed it as Cavinton for cerebrovascular disorders, stroke recovery, and vascular cognitive impairment.

Vinpocetine has a long clinical history in Central and Eastern Europe and parts of Asia as a cerebral vasodilator and neuroprotective agent, and it is popular among nootropic users for reported gains in cerebral blood flow, memory, and focus. Its reputation is genuinely divided: supportive trials exist but are often older or of limited quality, Western regulators never approved it as a drug, and in the United States authorities have questioned its status as a dietary supplement and warned against its use in pregnancy. It is thus seen at once as a time-tested medicine abroad and an evidence-thin, regulatory-gray supplement in the West.